Vical Inc Archives - San Diego Biotechnology Connection

Glaxo genital herpes vaccine flops but Agenus a buy in vaccine space

Vical genital herpes vaccine protects animals; human clinical testing

Stock Daily Change

Biotech Events in San Diego

@SDBiotech

San Diego Biotechnology Connection

Genital herpes vaccine, NIH, San Diego Biotechnology Connection

December 14, 2012 1 comment

By Rex Graham A Glaxo Smith Kline (Nasdaq: GSK) genital herpes vaccine recently flopped in a large clinical trial, but “next generation” genital herpes vaccines by Genocea Biosciences, Agenus, Inc. ( Read More

HSV-2 vaccine, Drexel University, San Diego Biotechnology Connection

May 23, 2012 no comments

By Rex Graham A paper published online May 22 in the Journal of General Virology reports that a genital herpes vaccine made by San Diego-based Vical, Inc. (Nasdaq: VICL) dramatically improved protect Read More

ADMP	0.695	-0.005
AEMD	0.0975	+0.0014
AHRO	0.73	0.00
AIMM	0.0035	0.00
AMGN	104.91	+0.38
ANX	0.733	0.00
APRI	2.635	-0.665
ARNA	7.98	+0.06
ATEC	1.91	0.00
AVNR	3.25	0.00
AVTO	0.005	0.00
AXMP	0.015	0.00
AXRX	0.16	0.00
CADX	6.74	+0.04
CELG	122.86	-0.58
CORX	0.045	0.00
CXM	0.0951	+0.0001
CYTX	2.43	-0.08
CYTR	2.27	-0.04
DRAD	2.39	-0.04
DXCM	20.05	-0.31
ENTB	0.0018	0.00
FOLD	3.4501	-0.0099
HALO	7.23	+0.06
HRBR	0.19	+0.0299
IAGXQ	0.14	0.00
ILMN	70.32	-0.37
IMBI	0.028	0.00
ISCO	0.26	-0.035
ISIS	20.57	+0.18
IVRO	0.0198	+0.0028
LGND	27.70	+0.32
LIFE	73.92	-0.18
LJPC	0.077	0.00
LPTN	4.9446	+0.0746
MCK	116.65	-0.90
MEDS	1.10	0.00
MEIP	8.40	-0.02
MLPH	0.018	0.00
MNKD	6.739	+0.509
MNOV	3.07	-0.11
MRIC	1.17	+0.02
NAII	4.5244	-0.1556
NBIX	12.18	+0.17
NRDCQ	0.0001	0.00
NUXP	0.0016	0.00
ONCS	0.312	+0.002
OPTR	14.30	-0.08
OREX	6.36	+0.17
PCRX	29.36	+0.28
PFE	28.95	-0.35
QDEL	21.45	-0.49
RHHBY	64.53	-1.12
RMD	49.56	-0.16
SNTS	21.99	-0.29
SQNM	3.96	+0.05
TSRX	7.624	+0.024
VOLC	16.76	+0.09
VRX	74.305	-0.515
VRNM	2.1401	-0.0499
VVUS	14.22	+0.70
ZGNX	1.4962	-0.0138

2013-05-23 10:32

Trius Therapeutics: New, Positive Dimension For Investment Outlook http://t.co/rcVXC57kkN $CBST $TEVA $TSRX
9 days ago
Retweet
@ilus_art Gorgeous way to celebrate art, biology and cells.
18 days ago
Retweet
Trius Therapeutics releases persuasive safety study of potent new antibiotic against MRSA #superbug. http://t.co/uRBiPHj14U
24 days ago
Retweet
Halozyme initiates Phase 2 trial of drug to treat stage 4 pancreatic cancer. http://t.co/U9cjxGbtIL
30 days ago
Retweet
Illumina’s stronger than expected revenue up 21% sends shares up 13%. http://t.co/qviU0MYLQ3
30 days ago
Retweet
Trius presenting clinical-trial results Apr. 27 http://t.co/MCFeBYi57w on tedizolid, a potent MRSA antibiotic. http://t.co/myB421ZD2n
30 days ago
Retweet
After Thermo Fisher Scientific buys Life Technologies, sequencing leader Illumina may finally sell. http://t.co/F92ndBP0z2
38 days ago
Retweet
http://t.co/y8xbsAQ4q8
62 days ago
Retweet
FDA reviewing diabetes drugs causing pancreas precancers. Affected: Lilly, Merck, Novo Nordisk, Bristol-Myers. http://t.co/2dPyRAYLsc
69 days ago
Retweet

23 Events on May 23, 2013 Studies Toward the Synthesis of Antitumor Natural Products Starts: 4:00 pm Ends: May 23, 2013 - 5:00 pm Location: Scripps Research Inst. - Green Hospital Building, Valerie Timken Amphitheater Description: Distinguished Lecture Series Speaker: John A. Porco, Ph.D., Professor, Department of Chemistry, Boston University Read More: <a href="http://pubs.rsc.org/en/content/articlelanding/2013/np/c3np20122h">link</a> More details...

The share price of Trius Therapeutics (TSRX) has rebounded almost fully from its 10 percent dip in the New Year that was triggered by its public offering of 7 million shares; however, uncertainty about the company’s lead investigational drug is a lingering February hangover. Small investors face a dilemma: should they dump their diluted shares, double down? Our story explains why we recommend doubling down: http://sandiegobiotechnology.com/topics/5733/trius-dump-or-double-down-on-maker-of-mrsa-antibiotic/
101 days ago
A Glaxo Smith Kline genital herpes vaccine recently flopped in a large clinical trial, but “next generation” genital herpes vaccines by Genocea Biosciences, Agenus, Inc., and San Diego-based Vical, Inc., offer new hope. http://sandiegobiotechnology.com/topics/5600/glaxo-genital-herpes-vaccine-flops-but-genocea-a-buy-in-vaccine-space/
160 days ago
The Dow was off 1.82 percent, down 243.36 points to 13,102.53 at the close of trading Oct. 23 amid disappointing earnings reports. But 11 publicly traded San Diego biotechs gained for the day. https://sandiegobiotechnology.com/topics/5443/eleven-san-diego-biotech-stocks-rise-amid-tuesday-plunge-in-dow/
211 days ago
Millions of infertile women will soon get the biggest baby boost in a generation from preimplantation genetic diagnosis (PGD), which identifies their healthiest embryos at in vitro fertilization (IVF) clinics. These blastocysts, embryos with 50-150 cells, are at a very favorable stage for implantation and pregnancy. The inner cell mass will give rise to the actual cells of the fetus. The other cells that surround and protect the inner cell mass give rise to the fetal part of the placenta. Photo: Robert Shabanowitz, Gesinger Medical Center
213 days ago
It’s more than a 5-hour energy jolt. Cardium Therapeutics’ purchase of To Go Brands and its nationwide marketing network will give the San Diego biotech company a permanent sales boost for its own nutritional supplements -- and a larger piece of the $30 billion supplements market. https://sandiegobiotechnology.com/topics/5393/cardium-boosts-energy-supplement-sales-with-national-marketing-muscle/
233 days ago